How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,430 results for

Skin Ulcer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Ulcerative colitis

Ulcerative colitis Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Ulcerative colitis Last reviewed: February 2019 Last updated: September 2018 Summary Ulcerative colitis is a type of inflammatory bowel disease characterised by diffuse inflammation of the colonic mucosa and a relapsing, remitting course. Patients commonly experience bloody diarrhoea, chronic diarrhoea (or both), lower abdominal (...) adenocarcinoma is a complication in 3% to 5% of patients. Definition Ulcerative colitis (UC) is a type of inflammatory bowel disease that characteristically involves the rectum and extends proximally to affect a variable length of the colon. It is recognised as a multifactorial polygenic disease, as the exact aetiology is still unknown. Included in the aetiological theories are environmental factors, immune dysfunction, and a likely genetic predisposition. Podolsky DK. Inflammatory bowel disease. N Engl J

2018 BMJ Best Practice

62. Assessment of oral ulceration

system'. J Oral Pathol Med. 2009 Mar;38(3):241-53. http://www.ncbi.nlm.nih.gov/pubmed/19141062?tool=bestpractice.com Simple: a single ulcer without the involvement of the remaining mucosa. Complex: a single or multiple ulcers with changes to the surrounding mucosa, skin, and/or systemic manifestations. The lesion may be white, red, or vesiculobullous. Destroying: diffuse lesion with tissue destruction and severe systemic involvement. Epidemiology Oral ulcerations are common, but most occurrences go (...) Assessment of oral ulceration Assessment of oral ulceration - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of oral ulceration Last reviewed: February 2019 Last updated: June 2018 Summary Oral mucosal ulcerations are common. Most are self-resolving and transient (e.g., after a simple cheek bite). However, some may require the intervention of a medical or dental practitioner. For example, the serious

2018 BMJ Best Practice

63. Pressure ulcer

are appropriate strategies to prevent pressure ulcers. Management of pressure ulcers is determined by the location and condition or severity of the wound. Wounds should be managed in accordance with wound care practices or policies. Definition Pressure ulcers have been defined by the National Pressure Ulcer Advisory Panel and the European Pressure Ulcer Advisory Panel as localised injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure or of pressure in combination (...) Pressure ulcer Pressure ulcer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Pressure ulcer Last reviewed: February 2019 Last updated: March 2018 Summary Pressure ulcers are commonly encountered in patients admitted to hospital and those in long-term care facilities. Older people, and all patients with limited mobility or impaired sensation, are at particular risk. Pressure damage most commonly occurs over bony

2018 BMJ Best Practice

64. Ulcerative colitis

Ulcerative colitis Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Ulcerative colitis Last reviewed: February 2019 Last updated: September 2018 Summary Ulcerative colitis is a type of inflammatory bowel disease characterised by diffuse inflammation of the colonic mucosa and a relapsing, remitting course. Patients commonly experience bloody diarrhoea, chronic diarrhoea (or both), lower abdominal (...) adenocarcinoma is a complication in 3% to 5% of patients. Definition Ulcerative colitis (UC) is a type of inflammatory bowel disease that characteristically involves the rectum and extends proximally to affect a variable length of the colon. It is recognised as a multifactorial polygenic disease, as the exact aetiology is still unknown. Included in the aetiological theories are environmental factors, immune dysfunction, and a likely genetic predisposition. Podolsky DK. Inflammatory bowel disease. N Engl J

2018 BMJ Best Practice

65. Extracorporeal shock wave therapy for the healing and management of venous leg ulcers. Full Text available with Trip Pro

Extracorporeal shock wave therapy for the healing and management of venous leg ulcers. Leg ulcers are chronic wounds of the lower leg, caused by poor blood flow, that can take a long time to heal. The pooling of blood in the veins can damage the skin and surrounding tissues, causing an ulcer to form. Venous leg ulcers are associated with impaired quality of life, reduced mobility, pain, stress and loss of dignity. The standard treatment for venous leg ulcers is compression bandages or stockings (...) of extracorporeal shock wave therapy in the healing and management of venous leg ulceration.Two review authors independently performed study selection. We planned that two review authors would also assess the risk of bias of included studies, extract study data and rate the certainty of the evidence using GRADE.We found no RCTs that met the inclusion criteria for this review.We found no RCTs assessing the effectiveness of extracorporeal shock wave therapy in the healing and management of venous leg ulceration

2018 Cochrane

66. WITHDRAWN: Interventions for skin changes caused by nerve damage in leprosy. Full Text available with Trip Pro

WITHDRAWN: Interventions for skin changes caused by nerve damage in leprosy. More than three million persons are disabled by leprosy worldwide. The main complication of sensory nerve damage is neuropathic ulceration, particularly of the feet. In this review we explored interventions that can prevent and treat secondary damage to skin and limbs.To assess the effects of self-care, dressings and footwear in preventing and healing secondary damage to the skin in persons affected by leprosy.We (...) searched the Cochrane Skin Group Specialised Register (April 2008), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2008), MEDLINE (from 2003 to April 2008), EMBASE (from 2005 to April 2008), CINAHL (1982-2006) and LILACS (1982- April 2008 ) as well as online registers of ongoing trials (April 2008).Randomised controlled trials involving anyone with leprosy and damage to peripheral nerves treated with any measures designed to prevent damage with the aim of healing

2019 Cochrane

67. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)

to the NHS in England, Wales, Scotland and Northern Ireland on Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma Description Cancer that starts in one part of the body can spread (metastasise) and form tumours on or below the skin elsewhere in the body, especially when the cancer is severe and widespread. These skin tumours can cause problems such as bleeding, pain or ulceration. In electrochemotherapy an anticancer drug is given by injection either into a vein (...) Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446) Overview | Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma | Guidance | NICE Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma Interventional procedures guidance [IPG446] Published date: March 2013 Share Save Guidance The National Institute for Health and Clinical Excellence (NICE) has issued full guidance

2013 National Institute for Health and Clinical Excellence - Interventional Procedures

68. Pressure ulcer

& Lifestyle Close Health in Norway Close Quality and Knowledge Close More topics Close Norwegian studies imply that between 7 (...) and 15 per cent of inpatients develop pressure ulcers . They develop more often in specific groups of patients, like patients with spinal cord injury, hip fracture and patients in intensive care. Pressure ulcers are areas of localized damage to the skin and underlying tissue, believed to be caused by pressure , shear force or friction. Pressure ulcers occur fast, it has been (...) in fewer pressure ulcers , or do they take up nurses’ time which could be better spent with the patient? An updated Cochrane review gives us (...) the current state of the evidence. Barts student nurses learning the ‘Australian lift’ in 1983 Looking back on my nurse training in the 1980s, it seems that efforts to prevent pressure ulcers were a really basic, and essential, part of caring for our patients. Any new reddening of the skin was like a mark of shame for the nurse looking after the bearer

2018 Trip Latest and Greatest

69. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis 22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab Procedure No. EMEA/H/C/004647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU (...) therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Zessly is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications

2018 European Medicines Agency - EPARs

70. Covid-19: Clinical Guidance for the Management of Skin Cancer Patients during the Coronavirus Pandemic

-differentiated tumours, perineural tumours, ulcerated and symptomatic lesions; lesions in patients with significant risk factors (while balancing the risk of COVID-19 complications for these high-risk patients). ? Consider deferring treatment of melanoma in situ for 2-3 months. British Association of Dermatologists & British Society for Dermatological Surgery COVID-19 – Skin cancer surgery guidance First published 24.03.20 (v 1); updated 26.03.30 (v 1.1), 30.03.20 (v1.2), 07.04.20 (v 1.3) 2 ? Consider (...) Covid-19: Clinical Guidance for the Management of Skin Cancer Patients during the Coronavirus Pandemic British Association of Dermatologists & British Society for Dermatological Surgery COVID-19 – Skin cancer surgery guidance First published 24.03.20 (v 1); updated 26.03.30 (v 1.1), 30.03.20 (v1.2), 07.04.20 (v 1.3) 1 CLINICAL GUIDANCE FOR THE MANAGEMENT OF SKIN CANCER PATIENTS DURING THE CORONAVIRUS PANDEMIC This is a very fluid situation and guidance may change over the next days

2020 British Association of Dermatologists

71. Squamous cell carcinoma of the skin

-coloured or erythematous plaques dome-shaped nodule exophytic, fungating, verrucous nodules or plaques ulcerated tumours lymphadenopathy bone pain hepatomegaly neurological signs UV radiation exposure immunosuppression fair skin human papillomavirus hereditary skin conditions older age male sex ionising radiation carcinogens actinic keratosis previous skin cancer tobacco smoking thiazide diuretics and cardiac drugs tattoos Diagnostic investigations biopsy CT body scan MRI scan PET scan FBC (...) Squamous cell carcinoma of the skin Squamous cell carcinoma of the skin - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Squamous cell carcinoma of the skin Last reviewed: February 2019 Last updated: August 2018 Summary Malignant tumour of keratinocytes arising in the epidermis of the skin. Second most common non-melanoma skin cancer worldwide, secondary to basal cell carcinoma. Cumulative ultraviolet exposure, most

2018 BMJ Best Practice

72. Overview of skin cancer

, flesh-coloured to erythematous, scaly plaques, while invasive SCC may present as an exophytic tumour or ulcer. [Figure caption and citation for the preceding image starts]: Squamous cell carcinoma on the ear with surrounding actinic damage From the collection of Dr Jessica M. Sheehan and Dr Keyoumars Soltani [Citation ends]. Tumours may be friable and bleed easily and are located mostly on sun-exposed areas of skin, such as the head and neck (84%) and extensor upper extremities (13%). Rundel RD (...) Overview of skin cancer Overview of skin cancer - Summary of relevant conditions | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Overview of skin cancer Last reviewed: February 2019 Last updated: June 2018 Introduction Skin cancer is the most common type of cancer worldwide. Possible risk factors include exposure to sunlight or UV radiation (e.g., tanning beds), viral infection (e.g., HPV), fair skin type, presence of large numbers or certain types

2018 BMJ Best Practice

73. Skin involvement in systemic sclerosis: rituximab

between the groups (p=0.68) Skin involvement in systemic sclerosis: rituximab (ES7) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 39 of 63Number of participants hospitalised 3/33 (9%) (2 with RTI and 1 with UTI) 10/18 (56%) (5 with RTI, 4 with UTI and 1 with digital ulcers) No statistical analysis Other adverse effects reported 1 HBV reactivation 2 mild infusion reactions No statistical analysis a This is within (...) Skin involvement in systemic sclerosis: rituximab Skin in Skin inv volv olvement in systemic sclerosis: rituximab ement in systemic sclerosis: rituximab Evidence summary Published: 7 March 2017 nice.org.uk/guidance/es7 pathways K Ke ey points y points The content of this evidence summary was up-to-date in March 2017. See summaries of product characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Regulatory status: Regulatory status

2017 National Institute for Health and Clinical Excellence - Advice

74. Accel-Heal for the management of non-healing venous leg ulcers

the head for patients with epilepsy. Adequate care is needed to ensure the device does not become wet. The device also needs to be removed prior to electrical investigations like magnetic resonance imaging, electroencephalograms and echocardiograms 1 . SHTG Innovative Medical Technology Overview | 2 Patient group Accel-Heal® is an adjunct treatment for managing patients with non-healing venous leg ulcers (VLUs) and those who are unable to use standard treatment. A VLU is an open skin lesion (...) recommendations. Wounds International. 2015. 5. Scottish Intercollegiate Guidelines Network. Management of chronic venous ulcer. 2010 [cited 2019 Jan 21]; Available from: https://www.sign.ac.uk/assets/sign120.pdf. 6. NHS Inform. Venous leg ulcer. 2019 [cited 2019 Jan 21]; Available from: https://www.nhsinform.scot/illnesses-and-conditions/skin-hair-and-nails/venous-leg-ulcer. 7. Bishop A, White R. Venous leg ulcers in the UK: the local burden of illness and the allocation of resources. Wounds UK. 2017;13(5

2019 SHTG Advice Statements

75. Tofacitinib (Xeljanz) - For the treatment of adult patients with moderately to severely active ulcerative colitis

submission from Crohn’s and Colitis UK, which is a registered charity. • Crohn’s and Colitis UK has received 5% pharmaceutical company funding in the past two years, with none from submitting company. 13 • The symptoms of ulcerative colitis, and their unpredictable nature can have a profound and devastating impact on all aspects of a person’s life. Frequent diarrhoea, abdominal pain and fatigue, anaemia, extra-intestinal manifestations such as joint, skin and eye problems, and the side effects (...) Tofacitinib (Xeljanz) - For the treatment of adult patients with moderately to severely active ulcerative colitis 1 Published 11 February 2019 1 SMC2122 tofacitinib 5mg, 10mg film-coated tablets (Xeljanz®) Pfizer Limited 11 January 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission

2019 Scottish Medicines Consortium

76. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers

care. NICE will consider reviewing this guidance when substantive new evidence becomes available. Wh Why the committee made these recommendations y the committee made these recommendations Standard care to prevent pressure ulcers in acute care settings includes risk assessment, skin assessment, regular repositioning and the use of special devices. Pressure ulcers are most common on the heel and sacrum. Mepilex Border Heel and Mepilex Border Sacrum dressings are designed to prevent pressure ulcers (...) Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers Mepile Mepilex Border Heel and Sacrum x Border Heel and Sacrum dressings for pre dressings for prev venting pressure ulcers enting pressure ulcers Medical technologies guidance Published: 10 January 2019 nice.org.uk/guidance/mtg40 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents

2019 National Institute for Health and Clinical Excellence - Medical technologies

77. Ulcerative Colitis in Adults

Ulcerative Colitis in Adults Downloaded from https://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3RQIKUrpuF/8trnhjhkg0Cnl84CZ9mTZr1JijOwub+Tc= on 03/06/2019 Downloaded from https://journals.lww.com/ajg by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3RQIKUrpuF/8trnhjhkg0Cnl84CZ9mTZr1JijOwub+Tc= on 03/06/2019 ACGClinicalGuideline:UlcerativeColitisinAdults DavidT.Rubin,MD,FACG 1 ,AshwinN.Ananthakrishnan,MD,MPH 2 ,CoreyA.Siegel,MD,MS 3 (...) ,buttherewasconsensusofsignificantclinicalmerit, “keyconcept”statementsweredevelopedusingexpert consensus.Theseguidelinesaremeanttobebroadlyapplicableandshouldbeviewedasthepreferred,butnotonly, approachtoclinicalscenarios. Am J Gastroenterol 2019;114:384–413. https://doi.org/10.14309/ajg.0000000000000152; published online February 22, 2019 INTRODUCTION Ulcerative colitis (UC) is a chronic disease a?ecting the large intestine, with an increasing incidence worldwide. Nearly 1 mil- lionindividualseachintheUnitedStatesandEuropearea?ected

2019 American College of Gastroenterology

78. Noncontact low-frequency ultrasound using the MIST Therapy System (Celleration Inc.) for treatment of venous leg ulcers

Noncontact low-frequency ultrasound using the MIST Therapy System (Celleration Inc.) for treatment of venous leg ulcers Noncontact low-frequency ultrasound using the MIST Therapy System (Celleration Inc.) for treatment of venous leg ulcers Noncontact low-frequency ultrasound using the MIST Therapy System (Celleration Inc.) for treatment of venous leg ulcers HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Noncontact low-frequency ultrasound using the MIST Therapy System (Celleration Inc.) for treatment of venous leg ulcers. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions The publication date for this report is June 30, 2016. A typographical error was corrected on August 3, 2017. See Publication History in the full report for details. Description of Technology The MIST Therapy

2018 Health Technology Assessment (HTA) Database.

79. Compression for venous leg ulcers

Media Releases 2013 Media Releases 2012 Media Releases Search Compression for venous leg ulcers Compression for venous leg ulcers Introduction Venous leg ulcers are the most common type of skin ulcer that mainly occur just above the ankle and usually affect older people and are more common in women; other signs include varicose veins and haemosiderin staining above the ankles (brown pigmentation). Intervention Medical compression therapy applied externally to the lower leg to provide a constant (...) (or butler or donner), is helpful for patients with limited strength or hand mobility or patients who have difficulty bending over (e.g. obesity, spine problems). Higher grade compression stockings may go on more easily if a light .liner sleeve is worn (eg Jobst Ulcer Care Compression Liners or a single layer of Tubifast retention bandage) is worn under the compression garment. Compression stockings absorb skin oils and cause the skin to dry out so the skin should be moisturised in the evening

2017 Handbook of Non-Drug interventions (HANDI)

80. Anabolic steroids for treating pressure ulcers. Full Text available with Trip Pro

Anabolic steroids for treating pressure ulcers. Pressure ulcers, also known as bed sores, pressure sores or decubitus ulcers develop as a result of a localised injury to the skin or underlying tissue, or both. The ulcers usually arise over a bony prominence, and are recognised as a common medical problem affecting people confined to a bed or wheelchair for long periods of time. Anabolic steroids are used as off-label drugs (drugs which are used without regulatory approval) and have been used (...) as adjuvants to usual treatment with dressings, debridement, nutritional supplements, systemic antibiotics and antiseptics, which are considered to be supportive in healing of pressure ulcers. Anabolic steroids are considered because of their ability to stimulate protein synthesis and build muscle mass. Comprehensive evidence is required to facilitate decision making, regarding the benefits and harms of using anabolic steroids.To assess the effects of anabolic steroids for treating pressure ulcers.In March

2017 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>